Macro Strategy - The report indicates that there is potential for interest rate cuts in 2026, with expectations of one rate cut or a 50 basis points reserve requirement ratio reduction, while retaining the possibility of two additional rate cuts depending on economic growth and financial market conditions [1][14]. Fixed Income Analysis - The semiconductor industry faces significant financing challenges due to its high capital intensity and long investment cycles. Despite the inclusion of semiconductor companies in the "bond technology board" for support, there remains a structural mismatch between the bond market's capabilities and the industry's needs, particularly for private companies [2]. - The report analyzes the bond financing strategies of three leading semiconductor companies: SK Hynix, ASML, and Broadcom, highlighting how their financing paths align with their strategic development phases [16][17]. Real Estate Policy Impact - The report evaluates the effects of housing loan interest subsidy policies, noting significant regional disparities in their effectiveness. For instance, Nanjing's Rain Flower District saw a 28.6% increase in residential sales, while other regions like Wuhan and Hangzhou experienced declines [3][19]. - If a nationwide 1% subsidy policy is implemented, the estimated fiscal cost could reach approximately 470 billion yuan, depending on the coverage of new and existing loans [4][19]. Company Recommendations - **Oriental Electric (600875)**: The company is expected to see steady growth in its energy equipment business, with projected net profits of 35.0 billion, 45.2 billion, and 54.4 billion yuan for 2025-2027, reflecting growth rates of 20%, 29%, and 20% respectively. A target price of 41.9 yuan is set, with a "buy" rating [5][21]. - **China Tobacco Hong Kong (06055.HK)**: The company is positioned to benefit from the unique export of cigarettes in the domestic duty-free market, with an upward adjustment in profit forecasts due to expected improvements in gross margins [6][22]. - **Liyang Chip (688135)**: The company is expanding its high-end testing capacity and is expected to continue growing, with a focus on automotive electronics and other emerging applications [7][8]. - **Sany Heavy Industry (600031)**: As a global leader in construction machinery, the company is projected to benefit from the industry recovery, with net profits forecasted at 85 billion, 111 billion, and 127 billion yuan for 2025-2027 [13].

Group 1: Market Performance - The A-share biopharmaceutical ETF Huatai Fuhua (159839) rose by 1.1%, with a total trading volume exceeding 22 million yuan, marking the fourth consecutive day of inflows totaling over 20 million yuan [2] - The Hong Kong biopharmaceutical ETF Huatai Fuhua (513280) fluctuated and closed flat, with a trading volume exceeding 42 million yuan, and a net inflow of over 17 million yuan in the last 60 days [3] - The majority of the popular component stocks in the biopharmaceutical ETF Huatai Fuhua (159839) showed positive performance, with Changchun High-tech hitting the daily limit and its subsidiary GenSci141 ointment receiving clinical trial approval [5] Group 2: Company Performance - WuXi AppTec (药明康德) reported a significant performance increase, with a projected net profit growth of 41.3% in 2025, driven by the TIDES business, which saw revenue growth exceeding 90% [8] - WuXi Biologics (药明生物) achieved a record total of 945 projects, with a 30% growth in dual monoclonal antibodies and ADC projects, indicating strong future revenue potential [8] - The domestic clinical CRO market is expected to return to a growth trajectory in 2025, benefiting companies like Tigermed (泰格医药) from improved order prices and increased clinical pipeline numbers [8] Group 3: Industry Trends - The global CXO industry is expected to continue its strong recovery, with significant investment and transaction demand in the biotech and pharmaceutical sectors anticipated to rebound in 2025 [7] - The Chinese innovative drug market is showing robust activity, with a 19% year-on-year increase in IND numbers and a substantial rise in BD transaction amounts, indicating a vibrant domestic market [7] - The Chinese innovative drug sector is transitioning from pipeline expectations to revenue realization, with over 70% of companies projected to achieve positive revenue growth in 2025 [11]

证券研究报告 东吴证券晨会纪要 东吴证券晨会纪要 2026-02-25 [Table_Tag] 宏观策略 [Table_MacroStrategy] 金融产品周报 20260207：海外市场流动性有企稳迹象，情绪或会好转【勘 误版】 市场行情展望：（2026.2.2-2026.2.6） 观点：市场短期进入结构混沌期， 但大盘指数仍然稳健。 2 月整体走势判断：2026 年 2 月，宏观择时模 型的月度评分是 0 分，历史上该分数万得全 A 指数后续一个月上涨概率 为 78.57%，平均涨幅为 3.37%。叠加日历效应中财报预告的结束，我们 对 2 月 A 股大盘走势持乐观的观点。但鉴于 1 月权益已累计不少盈利盘， 春节前可能有一定的止盈压力。 本周 A 股中，宽基 ETF 仍在持续流出, 但能观察到 1 月 30 日多数宽基 ETF 呈现明显成交额缩小的特征，说明 后续来自宽基 ETF 的抛压可能会逐步减小。同时通信、芯片、化工、石 油石化、港股非银等方向呈现资金流入的特征，可以关注后续资金的持续 性。 结构上，市场短期呈现混沌期特点。上周提示过的周期性行业表现 相对不错，石油、化工等方向仍旧较为稳健。但有 ...

可选消费板块下跌，中国中免（601888）跌超10%。 2月24日，港股收盘走低，恒生指数跌1.82%，恒生科技指数跌2.13%。 | 香港股票 △ | | | | --- | --- | --- | | 恒生指数 | 恒生科技 | 恒生生物科技 | | 26590.32 | 5270.70 15654.19 | | | -491.59 -1.82% -114.65 -2.13% -541.42 -3.34% | | | | 港股通消费 | 港股红利 | 港股现金流 | | 1704.19 | 2318.72 | 2555.21 | | -22.73 -1.32% -2.80 -0.12% -41.84 -1.61% | | | 互联网科技股集体走低，阿里巴巴跌2.7%，金山云跌5%，快手、小米等跌逾2%。 | 代码 | 名称 | 现价 | 涨跌 | 涨跌幅 ▲ | 成交额 | | --- | --- | --- | --- | --- | --- | | 0268 | 全蝶国际 | 9.970 c | -0.840 | -7.77% | 7.21亿 | | 0020 | 商沥-W | 2.610 c | - ...

Market Overview - The Hong Kong stock market experienced a decline across all major indices, with the Hang Seng Index falling by 1.82%, the Hang Seng Tech Index down by 2.13%, and the National Enterprises Index decreasing by 2.06% [1] - Major internet technology stocks also saw significant drops, including Tencent Holdings down nearly 3.3%, Alibaba down 2.7%, and Kingsoft Cloud down 5% [1] Stock Performance - Tencent Holdings closed at 188.29 billion, down 3.346% [2] - Xiaomi Group fell by 2.243%, closing at 51.03 billion [2] - Alibaba's stock decreased by 2.760%, ending at 148.00 billion [2] - Meituan saw a decline of 4.235%, closing at 55.24 billion [2] - China Duty Free Group experienced a significant drop of over 10.506%, closing at 8.37 billion [3] Sector Analysis - The robotics, pharmaceuticals, and duty-free sectors all faced declines, with China Duty Free Group dropping over 10%, and other companies like Tigermed and Zhaoyan New Drug falling by more than 3.6% and 7.3% respectively [3] - Conversely, Zhizhu saw a notable increase of over 12%, marking a rise of over 440% since its listing in January [3] Future Outlook - According to Liu Gang, a managing director at CICC, the credit cycle will determine index space, while industry trends will influence structural strength [3] - Short-term market adjustments may occur, but there is potential for upward correction after a pullback [3] - The mid-term outlook suggests a projected earnings growth of 3% to 4% for Hong Kong stocks, with the Hang Seng Index potentially rising to around 28,000 to 29,000 points [3] - The influx of capital from the south post-Chinese New Year is expected to provide liquidity support for the Hong Kong market [3] - Recommendations include focusing on technology (AI computing and applications), non-bank financials (insurance), and dividend stocks, with an emphasis on the need to confirm earnings and liquidity turning points for the Hang Seng Tech Index [3]

Market Performance - The Hang Seng Index closed down by 1.82% [1] - The Hang Seng Tech Index fell by 2.13% [1] Sector Performance - All sectors including internet technology, robotics, pharmaceuticals, and duty-free retail experienced declines [1] - China Duty Free Group saw a drop of over 10% [1] - Tigermed fell by over 3.6% [1] - Zhaoyan New Drug decreased by 7.3% [1] - Sanhua Intelligent Control dropped by 6.5% [1] Major Companies - Tencent Holdings declined by nearly 3.3% [1] - Alibaba decreased by 2.7% [1] - Kingsoft Cloud fell by 5% [1] - Kuaishou and Xiaomi both dropped by over 2% [1]

Group 1 - The Hong Kong stock market experienced a collective decline, with the Hang Seng Index falling by 1.82% and the Hang Seng Tech Index dropping by 2.13% [1] - Various sectors, including internet technology, robotics, pharmaceuticals, and duty-free, all saw declines, indicating a broad market downturn [1] - Notable declines included China Duty Free Group, which fell over 10%, and other companies such as Tigermed, which dropped by over 3.6%, and Zhaoyan New Drug, which fell by 7.3% [1] Group 2 - Major tech companies also faced losses, with Tencent Holdings down nearly 3.3%, Alibaba down 2.7%, and Kingsoft Cloud down 5% [1] - Other companies like Kuaishou and Xiaomi experienced declines of over 2%, reflecting a negative sentiment in the tech sector [1]

| 股票名称 | H股(港元) | A股 | 溢价率↓ | 偏离值 | | --- | --- | --- | --- | --- | | 东北电气(00042) | 0.315 | 2.25 | 757.14% | -50.71% | | 京城机电股份 | 4.380 | 14.1 | 285.62% | 12.60% | | (00187) | | | | | | 中石化油服(01033) | 1.010 | 3.22 | 282.18% | -2.51% | | 弘业期货(03678) | 3.190 | 9.96 | 273.98% | 2.61% | | 南京熊猫电子股份 | 5.280 | 14.78 | 235.23% | -0.03% | | (00553) | | | | | | 凯盛新能(01108) | 4.070 | 11.11 | 227.03% | 1.59% | | 钧达股份(02865) | 35.700 | 97.15 | 225.97% | -17.30% | | 复旦张江(01349) | 3.200 | 8.62 | 222.81% | -15.46% | | 安德利果 ...

近日，博纳西亚(杭州)医药科技股份有限公司(简称：博纳西亚)向港交所主板递交上市申请，兴证国 际、工银国际为其联席保荐人。 招股书显示，这家总部位于杭州的临床合同研究组织(CRO)致力于通过数字化赋能创新药临床研究，深 耕肿瘤及自身免疫性疾病两大领域，于2024年已取得约6729.1万元盈利。不过，与此同时，公司现金 流、应收账款状况面临考验，且公司市场份额并不占优，或将成为市场投资者担忧的因素。 在巨头林立的CRO行业，博纳西亚讲述的"小而美"故事，能否收获投资者青睐? 2025年业绩回暖 毛利率稳步上行 与行业平均水平相比，公司贸易应收款周转天数明显偏高。从2023年的44天，飙升至2024年的65天， 2025年前9个月进一步攀升至89天，远高于行业平均60天左右的水平。 应收款周转天数的快速上升表明，一方面，在生物医药融资环境虽然回暖但仍偏谨慎的背景下，博纳西 亚下游客户中资金紧张的生物医药企业占比可能上升，导致付款周期拉长;另一方面，博纳西亚的行业 地位处于弱势，也导致公司议价权相对薄弱。 据招股书披露，就2024年来自临床CRO服务的收入而言，博纳西亚在总部位于中国的市场参与者中排 名第14位，市 ...

近日，博纳西亚(杭州)医药科技股份有限公司(简称：博纳西亚)向港交所主板递交上市申请，兴证国 际、工银国际为其联席保荐人。 招股书显示，这家总部位于杭州的临床合同研究组织(CRO)致力于通过数字化赋能创新药临床研究，深 耕肿瘤及自身免疫性疾病两大领域，于2024年已取得约6729.1万元盈利。不过，与此同时，公司现金 流、应收账款状况面临考验，且公司市场份额并不占优，或将成为市场投资者担忧的因素。 在巨头林立的CRO行业，博纳西亚讲述的"小而美"故事，能否收获投资者青睐? 2025年业绩回暖 毛利率稳步上行 财务数据显示，博纳西亚的业绩在经历2024年的短暂回调后，于2025年重回增长轨道。公司于2023年 度、2024年度分别录得收入约为3.71亿元、3.40亿元(单位为人民币，下同)，年内利润为6241.2万元、 6729.1万元，其中2024年收入下滑主要受行业整体环境影响。 智通财经APP了解到，随着公司业务恢复增长，2025年截至9月30日止九个月，公司收入约为2.45亿， 相比去年同期的2.37亿元同比增长3.38%;期内利润为4522万元，相比去年同期的4456.2万元同比增长 1.48%。 | ...